Parabilis Reports 72.2% Response Rate at 32 Weeks in Zolucatetide Desmoid Tumor Trial

• Parabilis Medicines presented updated Phase 1/2 zolucatetide results in desmoid tumors at ESMO on October 24, 2026.
• Most evaluated patients experienced tumor shrinkage; no disease progression or treatment discontinuations due to treatment-related adverse events were reported.
• FDA alignment covered the selected regimen, a placebo-controlled trial design and progression-free survival as the primary endpoint.
• The PEDESTAL Phase 3 trial is planned to begin in the first half of 2027, with topline results expected in 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parabilis Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610240845PRIMZONEFULLFEED9852455) on October 24, 2026, and is solely responsible for the information contained therein.